Hay fever treatment: First OTC combination nasal spray launched

For the first time, a double-action combination treatment for moderate to severe hay fever has been available over the counter across UK pharmacies, offering a new option for those sufferers who remain uncontrolled on a corticosteroid or antihistamine nasal spray.

Launched by global healthcare company Viatris, Dymista® CONTROL (azelastine hydrochloride and fluticasone propionate) nasal spray— previously only available via prescription under the brand name Dymista — can be accessed without a GP visit.

The spray is intended for adults whose symptoms remain uncontrolled with a corticosteroid or antihistamine nasal spray.

Dymista® CONTROL (azelastine hydrochloride and fluticasone propionate) nasal spray

A recent survey commissioned by Viatris Healthcare UK Ltd revealed the impact of hay fever on the patients’ quality of life:

• 55 per cent of moderate to severe hay fever sufferers reported missing personal life milestones and celebrations, professional commitments or watching and playing sport due to their symptoms.
• 88 per cent respondents avoid attending outdoor activities during allergy season.
• Over a third said they cancel plans on a weekly or monthly basis during peak pollen times.

Dr. Helen Howells, GP with Specialist Role in Allergy, said: “As someone who suffers from hay fever myself, I know firsthand the challenges that living with hay fever can provide.”

“The symptoms can take over your life and make planning your day almost impossible.”

“The results from the survey show the impact that moderate to severe hay fever has on people, but with increased awareness and the treatment options available, individuals can feel empowered to regain control of their lives, especially this upcoming allergy season.”

Melissa Fisher, UK Country Manager at Viatris, emphasised that the company’s goal is to promote self-care and empower individuals to take charge of their lives, free from the concerns of hay fever interference.”

“This launch underscores our dedication to enhancing access to reliable, evidence-based treatments.”

“By improving access to care, we ensure that everyone in the UK has the resources to effectively manage their hay fever symptoms and feel empowered in doing so."

Understand hay fever

Also known as seasonal allergic rhinitis, hay fever is an inflammatory condition of the nasal passages triggered by allergens such as pollen, dust mites, and pet dander.

Affecting one in four people in the UK, symptoms include persistent sneezing, nasal congestion, itchy eyes, and fatigue.

Not only do these symptoms cause discomfort, but they also have serious implications, including reduced productivity and increased absenteeism.

Despite the range of treatments available, the survey found that many sufferers remain dissatisfied.

While antihistamine tablets and nasal sprays remain the most common measures taken for hay fever treatment, long-lasting relief emerged as the top priority for patients — yet one in ten said they were dissatisfied with their current choice.

Until now, patients who remained uncontrolled on either corticosteroid or antihistamine nasal sprays had no OTC combination option to manage their symptoms effectively.

Viatris has also released an infographic showcasing hay fever hot spots across the UK. Check here.